Vertex Pharma reports results and Vertex Pharma stock costs EUR 449.10 versus EUR 448.93
Published on 10/03/2026 at 10:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharmaceuticals Incorporated announced positive inaxaplin results on September 22, 2026, in a release published by Vertex Pharmaceuticals. Vertex Pharma stock was EUR 449.10 in weekend trading at Lang & Schwarz at 10:54 a.m. CEST on October 3, 2026, up 0.04 percent versus the EUR 448.93 close at Lang & Schwarz on October 2, 2026.
Weekend trading
The Lang & Schwarz price was EUR 449.10, compared with the EUR 448.93 close at Lang & Schwarz on October 2, 2026. The bid was EUR 448.20 and the ask was EUR 450.00. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.
Inaxaplin study results
In the Phase 2b AMPLIFIED study, inaxaplin produced a 42.70 percent reduction in urine albumin to creatinine ratio at Week 13 compared with baseline among people with APOL1-mediated kidney disease and modest proteinuria. In a cohort of people with APOL1-mediated kidney disease and type 2 diabetes, the reduction was 17.30 percent at Week 13 compared with baseline, according to the company release.
Next Xetra session
Vertex said it completed enrollment in the Phase 2/3 AMPLITUDE trial and remains on track to share interim-analysis results in early 2027. The next Xetra session is scheduled for October 5, 2026.
